Bryn Pharma, LLC (“Bryn” or the “Company”) is a privately-owned pharmaceutical organization committed to getting a better way for sufferers and caregivers to manage anaphylaxis, and today stated that it has opened into an accommodation with Aptar Pharma (AptarGroupNYSE: ATR), a first medication delivery methods provider, for the quantity and worldwide independent right to use Aptar’s novel, FDA-approved Bidose (BDS) nasal means for the delivery of epinephrine to manage anaphylaxis.
Up to 30 percent of sufferers who receive anaphylaxis will need a second dose of epinephrine to manage symptoms. Contemporary practice parameters recommend that doctors prescribe two epinephrine auto-injectors to be provided by their sufferers at all times.
This month, Bryn made dosing in its crucial clinical trial of its Epinephrine Nasal Spray (BRYN-NDS1C), using a single, compact, optimized Aptar BDS device capable of producing two therapeutic doses of epinephrine, following the need to take two epinephrine auto-injectors.
“Studies have shown that the bulk of people at the chance for anaphylaxis do not take two epinephrine auto-injectors with them at all times, putting them at greater risk of critical complications during an allergic reaction,” stated David Dworaczyk, Ph.D., CEO of Bryn Pharma.
“We are delighted to partner with Aptar Pharma to produce a product that can accommodate patients with a life-saving procedure that fits in a pocket, is straightforward to use, and complies with practice parameters.”
The Anaphylaxis Case
Anaphylaxis is a severe, life-threatening allergic response. The most frequent anaphylactic reactions are foods, insect stings, medicine, and latex. A notable difference between anaphylaxis and other allergic reactions is that anaphylaxis typically demands more than one system of the body.
Anaphylaxis needs immediate remedial treatment, driving about 100,000 emergency room visits in the U.S. each year.1,3 Because 30 percent of the sufferers who develop anaphylaxis will need a second dose of epinephrine to control symptoms, and use parameters suggest that doctors provide patients with two auto-injectors.4 If not adequately treated, anaphylaxis can be fatal.
The Bryn Pharma Case
Bryn Pharma was founded in 2016, is a personally held pharmaceutical business based by patients for sufferers. Bryn is focused on absolutely disrupting the existing market for epinephrine auto-injectors by delivering a convenient, easy-to-use option that better meets the requirements of patients.
Up to 49 million Americans may have food allergies and suffer anaphylaxis, and that number is growing annually. Bryn Pharma seeks to accommodate this growing patient population with A Better Way to be prepared for a life-threatening allergic reply. BRYN-NDS1C is not currently licensed for sale by the FDA or any international regulatory authority.
The Aptar Pharma Case
Aptar Pharma is a member of AptarGroup, Inc., a global head supplier of a broad range of innovative dispensing, sealing, and efficient packaging answers for the beauty, personal care, home care, prescription medicine, customer health care, injectables, food, and drink markets.
Aptar uses insights, design, communications, and science to create innovative packaging technologies that build brand value for its customers and, in turn, make a significant dispute in the lives, looks, health, and homes of people around the world. Aptar is headquartered in Crystal Lake, Illinois, and has over 14,000 dedicated representatives in 18 unconventional countries.
